ScreenerHero

MESOMesoblast Limited

NAS · US · Healthcare · Biotechnology · mesoblast.com
17.00USDMkt Cap: 2.20B $P/E: —

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.20B $
Enterprise Value2.25B $
Revenue (TTM)65.38M $
Gross Profit12.07M $
Net Income (TTM)-102.14M $
Revenue/Share0.5100 USD
Last Price17.00 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS5907171046
Valuation
P/E (Trailing)—
P/E (Forward)-290.50
PEG—
EV/EBITDA-34.99
EV/Revenue34.43
P/S34.57
P/B3.91
EPS (TTM)-0.81
EPS (Forward)-0.06
52W Range
16.8459% of range17.11
52W High17.11 USD
52W Low16.84 USD
Profitability
Gross Margin70.17%
Oper. Margin-55.16%
EBITDA Margin-98.40%
Profit Margin-593.92%
ROE-17.10%
ROA-13.02%
Growth
Revenue Growth1526.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.95M $
CapEx (TTM)730.00K $
FCF Margin-106.20%
FCF Yield-3.15%
Net Debt5.17M $
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity0.21
Current Ratio1.58
Quick Ratio1.35
Book Value/Sh4.460 USD
Cash/Share1.009 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:2
Split DateJan 10, 2024
Analyst Consensus
Rating—
Target (Mean)35.00 USD
Upside (mean)+105.9%
Target Range35.00 USD – 35.00 USD
# Analysts2
Ownership
Shares Out.129.70M
Float83.68M
Insiders5.04%
Institutions3.28%
Short Interest
Short Ratio11.3d
Short % Float3.35%
Short % Out.2.45%
Shares Short3.17M
Short (prev mo.)3.10M
Technical
SMA 5015.27 (+11.3%)
SMA 20016.01 (+6.2%)
Beta0.81
S&P 52W Chg21.00%
Avg Vol (30d)164.16K
Avg Vol (10d)201.51K
Technical Indicators
RSI (14)57.7
MACD0.4805
MACD Signal0.3461
MACD Hist.+0.1344
BB Upper18.09 USD
BB Middle15.77 USD
BB Lower13.45 USD
BB Width29.38%
ATR (14)0.6920 USD
Vol Ratio (20d)0.82x